Skip Navigation



Annals of Occupational Hygiene Advance Access published online on August 26, 2005
Annals of Occupational Hygiene, doi:10.1093/annhyg/mei042
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
49/7/629    most recent
mei042v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hedmer, M.
Right arrow Articles by Eksborg, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hedmer, M.
Right arrow Articles by Eksborg, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 British Occupational Hygiene Society
Received April 14, 2005
Accepted July 4, 2005

Article

Surface Contamination of Cyclophosphamide Packaging and Surface Contamination with Antineoplastic Drugs in a Hospital Pharmacy in Sweden

M. Hedmer 1*, A. Georgiadi 2, E. Rämme Bremberg 2, B. A. G. Jönsson 1, and S. Eksborg 3

1 Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, University Hospital, SE-221 85 Lund, Sweden
2 Karolinska Pharmacy, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
3 Karolinska Pharmacy, Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Woman and Child Health, Karolinska Institutet, SE-171 77 Stockholm, Sweden

* To whom correspondence should be addressed.
M. Hedmer, E-mail: maria.hedmer{at}med.lu.se


  Abstract

Workplaces, e.g. hospital pharmacies and hospital departments, where antineoplastic drugs are handled might be contaminated with these drugs, and pharmacy personnel and health care workers may be exposed. In this study potential sources for exposure of antineoplastic drugs were investigated. Unbroken drug vials and tablet blister packages, both containing cyclophosphamide (CP) and their outer packaging were wipe sampled. Analysis was performed by liquid chromatography combined with tandem mass spectrometry (LC-MS/MS). The result showed that almost every part of the primary packaging was contaminated with CP and ifosfamide (IF). However, the amounts of CP and IF were low, and most likely not harmful for the personnel handling these packaging in association with drug preparation. The contamination must originate from the pharmaceutical manufacturer. Different surfaces in the preparation unit of a Swedish hospital pharmacy were also investigated at two different occasions by wipe sampling. In the preparation unit CP and IF were found as contaminants on the majority of the investigated surfaces. After the first measurement the hospital pharmacy improved its routines. Lower amounts of CP and IF were detected at the second measurement. A low degree of contamination with CP and IF was also detected on the floor outside the preparation unit and this indicated a small distribution of antineoplastic drugs to the surroundings.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANN OCCUP HYGHome page
R. Schierl, A. Bohlandt, and D. Nowak
Guidance Values for Surface Monitoring of Antineoplastic Drugs in German Pharmacies
Ann. Hyg., October 1, 2009; 53(7): 703 - 711.
[Abstract] [Full Text] [PDF]

Home page
 ANN OCCUP HYGHome page
K. Touzin, J.-F. Bussieres, E. Langlois, M. Lefebvre, and C. Gallant
Cyclophosphamide Contamination Observed on the External Surfaces of Drug Vials and the Efficacy of Cleaning on Vial Contamination
Ann. Hyg., November 1, 2008; 52(8): 765 - 771.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
T. H. Connor and M. A. McDiarmid
Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings
CA Cancer J Clin, November 1, 2006; 56(6): 354 - 365.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.